Putting Science to Work

In the News

  • Aim to get back to around 20% revenue growth in FY18: Syngene

    Money Control-28/04/2017. The tie-up with the Canadia Company is a good start for the biologics business...

  • Initiator Pharma selects Syngene and Research Toxicology Centre (RTC) as primary partners for the preclinical development of IPED2015.

    Cision News-19/04/2017. Initiator Pharma has selected Syngene, India and Research Toxicology Centre, Italy ( RTC) as contract research organizations (CROs) to conduct the pre-clinical development of the drug candidate IPED2015 for the treatment of ED.

  • Biologics and Biosimilars -Promising field for medicines for the future by Dr. Dhananjay Patankar (Head-Pharmaceutical and Biopharmaceutical Development)

    Pharma Focus Asia-09/03/2017. As per Make in India campaign by the government, Indian biotech industry, comprising bio pharmaceuticals, is expected to grow at a rate of 30 per cent a year and reach US$100 billion by 2025.

  • Syngene to co-develop nutrition products for Herbalife

    Business Standard-02/03/2017. It is Syngene's fifth dedicated facility and second for nutrition research, the lab is a testimony of its capabilities to deliver innovative solutions in wide industry segments.

  • Herbalife teams up with Syngene to develop, formulate nutrition products

    The Hindu Businessline-02/03/2017. The new nutrition R&D facility will be housed within the Syngene campus, with around 10 Syngene scientists working on Herbalife formulations.

  • Clinical trials in India – Changing regulatory environment - by Dr. Chetan Tamhankar (Head -Clinical Development Services)

    Pharmabiz-01/02/2017. The recent regulatory and policy changes announced by the government has once again made clinical trials in India lucrative for the global healthcare industry.

  • Syngene International Q3 net profit up 11.54% at Rs 74 cr

    Outlook-24/01/2017. We made good progress on client service delivery across all of business verticals despite a fire incident damaging one of our research facilities, effective implementation of our business continuity plan..

  • Syngene International: Discover the chemistry

    The Hindu Businessline-30/10/2016. From a pure play research services company, catering to the research needs of innovative pharma companies, Syngene is now repositioning itself as a fully integrated contract research and manufacturing company.

  • Syngene posts 55% rise in net profit

    Live Mint-20/10/2016. Profit rose to Rs75 crore in the second quarter, from Rs48 crore a year earlier. Revenue rose 22% increase to Rs.319 crore from Rs.262 crore...

  • Syngene International acquires Strand Life Sciences’s assets.

    Live Mint-22/09/2016. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities...

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

FB Side
Inactive